Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.42
MRK's Cash-to-Debt is ranked lower than
71% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. MRK: 0.42 )
Ranked among companies with meaningful Cash-to-Debt only.
MRK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 0.71 Max: 6.12
Current: 0.42
0.29
6.12
Equity-to-Asset 0.42
MRK's Equity-to-Asset is ranked lower than
77% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
MRK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.45 Max: 0.53
Current: 0.42
0.34
0.53
Debt-to-Equity 0.71
MRK's Debt-to-Equity is ranked lower than
72% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. MRK: 0.71 )
Ranked among companies with meaningful Debt-to-Equity only.
MRK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.34 Max: 0.72
Current: 0.71
0.03
0.72
Debt-to-EBITDA 3.11
MRK's Debt-to-EBITDA is ranked lower than
57% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. MRK: 3.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MRK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.53  Med: 1.19 Max: 3.11
Current: 3.11
0.53
3.11
Interest Coverage 6.38
MRK's Interest Coverage is ranked lower than
73% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. MRK: 6.38 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 10.18 Max: 20.13
Current: 6.38
4.14
20.13
Piotroski F-Score: 7
Altman Z-Score: 3.02
Beneish M-Score: -2.62
WACC vs ROIC
6.84%
6.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.93
MRK's Operating Margin % is ranked higher than
78% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. MRK: 11.93 )
Ranked among companies with meaningful Operating Margin % only.
MRK' s Operating Margin % Range Over the Past 10 Years
Min: 6.43  Med: 16.53 Max: 21.86
Current: 11.93
6.43
21.86
Net Margin % 7.15
MRK's Net Margin % is ranked higher than
73% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. MRK: 7.15 )
Ranked among companies with meaningful Net Margin % only.
MRK' s Net Margin % Range Over the Past 10 Years
Min: 1.87  Med: 13.05 Max: 47.03
Current: 7.15
1.87
47.03
ROE % 7.07
MRK's ROE % is ranked higher than
69% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. MRK: 7.07 )
Ranked among companies with meaningful ROE % only.
MRK' s ROE % Range Over the Past 10 Years
Min: 1.51  Med: 11.48 Max: 42.27
Current: 7.07
1.51
42.27
ROA % 3.00
MRK's ROA % is ranked higher than
58% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. MRK: 3.00 )
Ranked among companies with meaningful ROA % only.
MRK' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 5.9 Max: 16.34
Current: 3
0.79
16.34
ROC (Joel Greenblatt) % 29.98
MRK's ROC (Joel Greenblatt) % is ranked higher than
87% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. MRK: 29.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MRK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.88  Med: 44.45 Max: 105.49
Current: 29.98
10.88
105.49
3-Year Revenue Growth Rate -0.90
MRK's 3-Year Revenue Growth Rate is ranked lower than
72% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: -0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MRK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.5  Med: 8.4 Max: 22.8
Current: -0.9
-16.5
22.8
3-Year EBITDA Growth Rate -4.50
MRK's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. MRK: -4.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MRK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 8.1 Max: 44.8
Current: -4.5
-17.6
44.8
3-Year EPS without NRI Growth Rate -1.40
MRK's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. MRK: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: 12.2 Max: 73.8
Current: -1.4
-29.3
73.8
GuruFocus has detected 3 Warning Signs with Merck & Co Inc MRK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MRK's 30-Y Financials

Financials (Next Earnings Date: 2018-02-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

MRK Guru Trades in Q4 2016

Jeremy Grantham 13,700 sh (+82.67%)
John Buckingham 31,185 sh (+22.01%)
Manning & Napier Advisors, Inc 379,630 sh (+12.99%)
Murray Stahl 47,880 sh (+5.24%)
Mairs and Power 97,839 sh (+0.93%)
Pioneer Investments 606,522 sh (+0.67%)
Jeff Auxier 153,453 sh (+0.20%)
David Dreman 710 sh (unchged)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
Stanley Druckenmiller 683,800 sh (unchged)
David Carlson 275,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
Tweedy Browne Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,959,100 sh (-0.18%)
Ken Fisher 6,802,264 sh (-0.22%)
Kahn Brothers 952,741 sh (-0.55%)
Mario Gabelli 106,605 sh (-0.74%)
Charles Brandes 2,690,441 sh (-4.33%)
Barrow, Hanley, Mewhinney & Strauss 17,668,105 sh (-4.91%)
Richard Pzena 1,260,853 sh (-10.49%)
Joel Greenblatt 287,063 sh (-13.22%)
Vanguard Health Care Fund 35,181,618 sh (-15.26%)
Dodge & Cox 13,947,142 sh (-23.90%)
Richard Snow 407,174 sh (-48.61%)
Paul Tudor Jones 9,900 sh (-98.38%)
» More
Q1 2017

MRK Guru Trades in Q1 2017

Tweedy Browne 3,306 sh (New)
Steven Cohen 155,000 sh (New)
Jim Simons 7,363,034 sh (New)
Caxton Associates 7,900 sh (New)
Signature Select Canadian Fund 33,950 sh (New)
Paul Tudor Jones 168,527 sh (+1602.29%)
Joel Greenblatt 767,331 sh (+167.30%)
PRIMECAP Management 4,875,300 sh (+64.76%)
John Buckingham 32,088 sh (+2.90%)
Manning & Napier Advisors, Inc 383,314 sh (+0.97%)
Ken Fisher 6,862,961 sh (+0.89%)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
David Dreman Sold Out
Stanley Druckenmiller Sold Out
Mario Gabelli 105,805 sh (-0.75%)
Kahn Brothers 940,119 sh (-1.32%)
Pioneer Investments 597,088 sh (-1.56%)
Dodge & Cox 13,689,174 sh (-1.85%)
Jeff Auxier 149,153 sh (-2.80%)
Charles Brandes 2,606,115 sh (-3.13%)
Murray Stahl 46,324 sh (-3.25%)
Mairs and Power 90,144 sh (-7.86%)
Vanguard Health Care Fund 32,271,044 sh (-8.27%)
Barrow, Hanley, Mewhinney & Strauss 15,815,276 sh (-10.49%)
Richard Snow 318,316 sh (-21.82%)
Richard Pzena 826,233 sh (-34.47%)
Jeremy Grantham 7,600 sh (-44.53%)
» More
Q2 2017

MRK Guru Trades in Q2 2017

Ray Dalio 13,227 sh (New)
Stanley Druckenmiller 755,500 sh (New)
Pioneer Investments 690,621 sh (+15.66%)
Manning & Napier Advisors, Inc 441,029 sh (+15.06%)
John Buckingham 36,755 sh (+14.54%)
Caxton Associates 9,000 sh (+13.92%)
Murray Stahl 49,262 sh (+6.34%)
PRIMECAP Management 5,111,500 sh (+4.84%)
Ken Fisher 7,100,308 sh (+3.46%)
Jeff Auxier 149,213 sh (+0.04%)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Mario Gabelli 105,805 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tweedy Browne 3,306 sh (unchged)
Steven Cohen 550,000 sh (unchged)
T Rowe Price Equity Income Fund 3,370,700 sh (-0.13%)
Richard Pzena 824,940 sh (-0.16%)
Kahn Brothers 932,840 sh (-0.77%)
Dodge & Cox 13,557,699 sh (-0.96%)
Barrow, Hanley, Mewhinney & Strauss 15,542,519 sh (-1.72%)
Mairs and Power 85,121 sh (-5.57%)
Vanguard Health Care Fund 30,067,944 sh (-6.83%)
Steven Cohen 132,300 sh (-14.65%)
Charles Brandes 2,190,048 sh (-15.97%)
Jeremy Grantham 6,300 sh (-17.11%)
Jim Simons 4,592,134 sh (-37.63%)
Joel Greenblatt 120,462 sh (-84.30%)
Paul Tudor Jones 8,940 sh (-94.70%)
Richard Snow 5,327 sh (-98.33%)
Eaton Vance Worldwide Health Sciences Fund 136,719 sh (-44.67%)
» More
Q3 2017

MRK Guru Trades in Q3 2017

George Soros 3,500 sh (New)
Jeremy Grantham 74,800 sh (+1087.30%)
Steven Cohen 915,954 sh (+592.33%)
Pioneer Investments 3,560,465 sh (+415.55%)
First Eagle Investment 27,790 sh (+256.74%)
Richard Pzena 1,519,959 sh (+84.25%)
Joel Greenblatt 154,317 sh (+28.10%)
John Buckingham 44,822 sh (+21.95%)
PRIMECAP Management 5,426,300 sh (+6.16%)
Mairs and Power 88,203 sh (+3.62%)
Manning & Napier Advisors, Inc 455,073 sh (+3.18%)
Jeff Auxier 153,653 sh (+2.98%)
Ken Fisher 7,292,315 sh (+2.70%)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Richard Snow 5,327 sh (unchged)
Tweedy Browne 3,306 sh (unchged)
Steven Cohen 1,500,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 136,719 sh (unchged)
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Dodge & Cox 13,462,469 sh (-0.70%)
Murray Stahl 48,869 sh (-0.80%)
Kahn Brothers 918,730 sh (-1.51%)
Barrow, Hanley, Mewhinney & Strauss 15,122,702 sh (-2.70%)
Vanguard Health Care Fund 29,209,044 sh (-2.86%)
Mario Gabelli 101,905 sh (-3.69%)
T Rowe Price Equity Income Fund 3,191,200 sh (-5.33%)
Jim Simons 4,014,063 sh (-12.59%)
Charles Brandes 1,598,786 sh (-27.00%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -2.86%0.12%$61.49 - $66.16 $ 54.27-15%29,209,044
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -2.70%0.04%$61.49 - $66.16 $ 54.27-15%15,122,702
Dodge & Cox 2017-09-30 Reduce -0.70%0.01%$61.49 - $66.16 $ 54.27-15%13,462,469
Ken Fisher 2017-09-30 Add 2.70%0.02%$61.49 - $66.16 $ 54.27-15%7,292,315
T Rowe Price Equity Income Fund 2017-09-30 Reduce -5.33%0.05%$61.49 - $66.16 $ 54.27-15%3,191,200
Charles Brandes 2017-09-30 Reduce -27.00%0.6%$61.49 - $66.16 $ 54.27-15%1,598,786
Richard Pzena 2017-09-30 Add 84.25%0.23%$61.49 - $66.16 $ 54.27-15%1,519,959
Kahn Brothers 2017-09-30 Reduce -1.51%0.14%$61.49 - $66.16 $ 54.27-15%918,730
Joel Greenblatt 2017-09-30 Add 28.10%0.03%$61.49 - $66.16 $ 54.27-15%154,317
Mario Gabelli 2017-09-30 Reduce -3.69%$61.49 - $66.16 $ 54.27-15%101,905
First Eagle Investment 2017-09-30 Add 256.74%$61.49 - $66.16 $ 54.27-15%27,790
George Soros 2017-09-30 New Buy0.01%$61.49 - $66.16 $ 54.27-15%3,500
Vanguard Health Care Fund 2017-06-30 Reduce -6.83%0.31%$61.89 - $66.16 $ 54.27-15%30,067,944
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -1.72%0.03%$61.89 - $66.16 $ 54.27-15%15,542,519
Dodge & Cox 2017-06-30 Reduce -0.96%0.01%$61.89 - $66.16 $ 54.27-15%13,557,699
Ken Fisher 2017-06-30 Add 3.46%0.02%$61.89 - $66.16 $ 54.27-15%7,100,308
T Rowe Price Equity Income Fund 2017-06-30 Reduce -0.13%$61.89 - $66.16 $ 54.27-15%3,370,700
Charles Brandes 2017-06-30 Reduce -15.97%0.39%$61.89 - $66.16 $ 54.27-15%2,190,048
Kahn Brothers 2017-06-30 Reduce -0.77%0.08%$61.89 - $66.16 $ 54.27-15%932,840
Richard Pzena 2017-06-30 Reduce -0.16%$61.89 - $66.16 $ 54.27-15%824,940
Joel Greenblatt 2017-06-30 Reduce -84.30%0.52%$61.89 - $66.16 $ 54.27-15%120,462
Vanguard Health Care Fund 2017-03-31 Reduce -8.27%0.41%$59.92 - $66.58 $ 54.27-15%32,271,044
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -10.49%0.16%$59.92 - $66.58 $ 54.27-15%15,815,276
Dodge & Cox 2017-03-31 Reduce -1.85%0.01%$59.92 - $66.58 $ 54.27-15%13,689,174
Ken Fisher 2017-03-31 Add 0.89%0.01%$59.92 - $66.58 $ 54.27-15%6,862,961
Charles Brandes 2017-03-31 Reduce -3.13%0.07%$59.92 - $66.58 $ 54.27-15%2,606,115
Kahn Brothers 2017-03-31 Reduce -1.32%0.13%$59.92 - $66.58 $ 54.27-15%940,119
Richard Pzena 2017-03-31 Reduce -34.47%0.14%$59.92 - $66.58 $ 54.27-15%826,233
Joel Greenblatt 2017-03-31 Add 167.30%0.39%$59.92 - $66.58 $ 54.27-15%767,331
Mario Gabelli 2017-03-31 Reduce -0.75%$59.92 - $66.58 $ 54.27-15%105,805
Tweedy Browne 2017-03-31 New Buy0.01%$59.92 - $66.58 $ 54.27-15%3,306
David Dreman 2017-03-31 Sold Out 0.02%$59.92 - $66.58 $ 54.27-15%0
Vanguard Health Care Fund 2016-12-31 Reduce -15.26%0.85%$58.43 - $64.96 $ 54.27-12%35,181,618
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -4.91%0.09%$58.43 - $64.96 $ 54.27-12%17,668,105
Dodge & Cox 2016-12-31 Reduce -23.90%0.26%$58.43 - $64.96 $ 54.27-12%13,947,142
Ken Fisher 2016-12-31 Reduce -0.22%$58.43 - $64.96 $ 54.27-12%6,802,264
Charles Brandes 2016-12-31 Reduce -4.33%0.11%$58.43 - $64.96 $ 54.27-12%2,690,441
Richard Pzena 2016-12-31 Reduce -10.49%0.06%$58.43 - $64.96 $ 54.27-12%1,260,853
Kahn Brothers 2016-12-31 Reduce -0.55%0.06%$58.43 - $64.96 $ 54.27-12%952,741
Joel Greenblatt 2016-12-31 Reduce -13.22%0.04%$58.43 - $64.96 $ 54.27-12%287,063
Mario Gabelli 2016-12-31 Reduce -0.74%$58.43 - $64.96 $ 54.27-12%106,605
Tweedy Browne 2016-12-31 Sold Out 0.01%$58.43 - $64.96 $ 54.27-12%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, XSWX:NOVN, XPAR:SAN, XSWX:ROG, XTER:BAYN, NYSE:PFE, NYSE:BMY, NYSE:LLY, LSE:GSK, LSE:AZN, TSE:4503, TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, TSE:4151, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. From a geographical perspective, close to half of the company's sales are generated in the United States.

Top Ranked Articles about Merck & Co Inc

US Market Indexes Lower for the Week Dow Jones closes at 23,422.21
U.S. market indexes were mostly lower on Friday. The Dow Jones Industrial Average closed at 23,422.21 for a loss of -39.73 points or -0.17%. The S&P 500 closed at 2,582.30 for a loss of -2.32 points or -0.09%. The Nasdaq Composite closed at 6,750.94 for a gain of 0.89 points or 0.01%. The VIX Volatility Index was higher at 11.21 with a gain of 0.71 points or 6.76%. Read more...
52-Week Company Lows Prices for AT&T, GE, Merck, CVS Health, Time Warner and TJX Companies fall
According to GuruFocus’ list, these stocks have reached their 52-week lows. Read more...
US Market Indexes Gain on Wednesday Dow Jones, S&P 500 and Nasdaq Composite report new highs
U.S. market indexes were higher on Wednesday. The Dow Jones Industrial Average closed at 23,563.36 for a gain of 6.13 points or 0.03%. The S&P 500 closed at 2,594.38 for a gain of 3.74 points or 0.14%. The Nasdaq Composite closed at 6,789.12 for a gain of 21.34 points or 0.32%. The VIX Volatility Index was lower for the day at 9.73 with a loss of -0.16 points or -1.62%. Read more...
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
Apple's Earnings Help Stocks Gain on Friday US market indexes higher for the week
U.S. market indexes were higher on Friday. Read more...
52-Week Company Lows AT&T, GE, Merck, Kraft Heinz, CVS and Twenty-First Century Fox prices tumble
According to GuruFocus' list, these stocks have reached their 52-week lows. Read more...
US Market Indexes Gain in October Nasdaq Composite closes at new high of 6,727.67 on Tuesday
U.S. market indexes were higher on Wednesday. The Dow Jones Industrial Average closed at 23,377.24 for a gain of 28.50 points or 0.12%. The S&P 500 closed at 2,575.26 for a gain of 2.43 points or 0.09%. The Nasdaq Composite closed at 6,727.67 for a gain of 28.71 points or 0.43%. The VIX Volatility Index was lower for the day at 10.17 for a loss of -0.33 points or -3.14%. Read more...
Detailed Research: Economic Perspectives on Gap, Cleveland-Cliffs, Altria, Express, Merck & Co., and Halliburton – What Drives Growth in Today's Competitive Landscape
US Market Indexes Lower on Monday Dow Jones closes at 23,348.74
U.S. market indexes were lower Monday. Read more...
Financial Markets Open Lower After Record Highs Cooper Tire & Rubber falls on missed revenue, lower guidance
Wall Street was down in Monday premarket trading with the main indexes in red at the start of an important week for the U.S. economy with central bank decisions. Read more...

Ratios

vs
industry
vs
history
PE Ratio 52.18
MRK's PE Ratio is ranked lower than
66% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. MRK: 52.18 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 22.79 Max: 138.33
Current: 52.18
6.33
138.33
Forward PE Ratio 13.12
MRK's Forward PE Ratio is ranked higher than
62% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. MRK: 13.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 52.18
MRK's PE Ratio without NRI is ranked lower than
66% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. MRK: 52.18 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 22.79 Max: 138.33
Current: 52.18
6.33
138.33
PB Ratio 3.87
MRK's PB Ratio is ranked lower than
70% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. MRK: 3.87 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.24 Max: 7.25
Current: 3.87
1.72
7.25
PS Ratio 3.76
MRK's PS Ratio is ranked lower than
63% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. MRK: 3.76 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.38 Max: 5.48
Current: 3.76
2.01
5.48
Price-to-Free-Cash-Flow 34.72
MRK's Price-to-Free-Cash-Flow is ranked higher than
58% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. MRK: 34.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.7 Max: 88.07
Current: 34.72
7.88
88.07
Price-to-Operating-Cash-Flow 24.80
MRK's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. MRK: 24.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 14.29 Max: 35.61
Current: 24.8
6.68
35.61
EV-to-EBIT 40.67
MRK's EV-to-EBIT is ranked lower than
68% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. MRK: 40.67 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 19.1 Max: 52.5
Current: 40.67
4.9
52.5
EV-to-EBITDA 18.85
MRK's EV-to-EBITDA is ranked higher than
51% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. MRK: 18.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.8 Max: 22.6
Current: 18.85
4.2
22.6
EV-to-Revenue 4.12
MRK's EV-to-Revenue is ranked lower than
63% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. MRK: 4.12 )
Ranked among companies with meaningful EV-to-Revenue only.
MRK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.75 Max: 5.5
Current: 4.12
1.9
5.5
Shiller PE Ratio 25.08
MRK's Shiller PE Ratio is ranked higher than
62% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. MRK: 25.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.24  Med: 17.33 Max: 30.63
Current: 25.08
8.24
30.63
Current Ratio 1.43
MRK's Current Ratio is ranked lower than
72% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. MRK: 1.43 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.51 Max: 3.7
Current: 1.43
0.97
3.7
Quick Ratio 1.16
MRK's Quick Ratio is ranked lower than
68% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. MRK: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.19 Max: 3.44
Current: 1.16
0.69
3.44
Days Inventory 149.01
MRK's Days Inventory is ranked lower than
64% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. MRK: 149.01 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 108.49  Med: 130.49 Max: 205.16
Current: 149.01
108.49
205.16
Days Sales Outstanding 70.34
MRK's Days Sales Outstanding is ranked higher than
55% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. MRK: 70.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 59.4 Max: 87.87
Current: 70.34
44.5
87.87
Days Payable 75.29
MRK's Days Payable is ranked higher than
59% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. MRK: 75.29 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 37.12  Med: 47.38 Max: 90.81
Current: 75.29
37.12
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.45
MRK's Dividend Yield % is ranked higher than
79% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. MRK: 3.45 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.51  Med: 3.58 Max: 6.68
Current: 3.45
2.51
6.68
Dividend Payout Ratio 1.81
MRK's Dividend Payout Ratio is ranked lower than
73% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 1.81 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.85 Max: 5.43
Current: 1.81
0.27
5.43
3-Year Dividend Growth Rate 2.30
MRK's 3-Year Dividend Growth Rate is ranked lower than
61% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. MRK: 2.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 31
Current: 2.3
0
31
Forward Dividend Yield % 3.48
MRK's Forward Dividend Yield % is ranked higher than
76% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. MRK: 3.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.02
MRK's 5-Year Yield-on-Cost % is ranked higher than
71% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. MRK: 4.02 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.92  Med: 4.17 Max: 7.78
Current: 4.02
2.92
7.78
3-Year Average Share Buyback Ratio 2.10
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. MRK: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.9  Med: 1 Max: 2.8
Current: 2.1
-12.9
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 31.01
MRK's Price-to-Tangible-Book is ranked lower than
96% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. MRK: 31.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MRK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 11 Max: 3112.5
Current: 31.01
3.19
3112.5
Price-to-Intrinsic-Value-Projected-FCF 1.39
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. MRK: 1.39 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.51 Max: 3.48
Current: 1.39
0.75
3.48
Price-to-Median-PS-Value 1.11
MRK's Price-to-Median-PS-Value is ranked lower than
71% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. MRK: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.19 Max: 2.11
Current: 1.11
0.63
2.11
Price-to-Graham-Number 8.48
MRK's Price-to-Graham-Number is ranked lower than
94% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. MRK: 8.48 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MRK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.26 Max: 31.92
Current: 8.48
1.09
31.92
Earnings Yield (Greenblatt) % 2.46
MRK's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. MRK: 2.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.2 Max: 20.6
Current: 2.46
1.9
20.6
Forward Rate of Return (Yacktman) % 0.09
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
66% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. MRK: 0.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.7  Med: 7.3 Max: 20.4
Current: 0.09
-5.7
20.4

More Statistics

Revenue (TTM) (Mil) $39,804.00
EPS (TTM) $ 1.04
Beta0.88
Short Percentage of Float0.62%
52-Week Range $53.63 - 66.80
Shares Outstanding (Mil)2,724.44

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 40,109 40,761 42,610 43,152
EPS ($) 3.94 4.09 4.52 4.68
EPS without NRI ($) 3.94 4.09 4.52 4.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.95%
Dividends per Share ($) 1.90 1.96 1.97

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}